PRESS & NEWS

Tact.ai, la société d'engagement client pour les sciences de la vie, a annoncé la nomination de deux nouveaux conseillers du conseil d'administration issus de l'industrie pharmaceutique : Giuseppe Firenze, responsable de l'information commerciale mondiale chez Eli Lilly and Company, et Desmond Creary, responsable de l'engagement client chez Novartis US. Giuseppe et Desmond joueront un rôle clé dans le développement des capacités avancées de la plateforme pour permettre de fournir plus rapidemen

Tact.ai, das Kundenengagement-Unternehmen für Life Sciences, hat die Ernennung von zwei neuen Board Advisors aus der Pharmaindustrie bekanntgegeben: Giuseppe Firenze, Global Commercial Information Officer von Eli Lilly and Company und Desmond Creary, Chief Customer Engagement Officer für Novartis US. Giuseppe Firenze und Desmond Creary werden eine wichtige Rolle bei der Entwicklung der erweiterten Funktionen der Plattform übernehmen, um möglichst viele Patienten schneller mit innovativen Medikam

Tact.ai welcomes two new pharma executives as board advisors to accelerate innovation in life sciences customer engagement. Giuseppe Firenze, Global Commercial Information Officer of Eli Lilly and Company, and Desmond Creary, Chief Customer Engagement Officer for Novartis US. Giuseppe and Desmond will play key roles in the development of the platform’s advanced capabilities to help deliver innovative medicines to more patients faster.

Tact.ai, the customer engagement company for life sciences,announced today a set of new capabilities that improve customer access for thefield. The new capabilities help teams appear in customer inboxes morefrequently, and work where the HCPs want to work – like Microsoft Teams forremote engagement – in a compliant way whilst providing them the data &content they need to deliver personalized journeys across all channels.

Tact.ai, the customer engagement company for life sciences, announced today that former Novartis Pharma Global CIO and SVP, Andreas Müller, has joined the company as an Advisor. His role will focus on working with commercial and medical leaders to accelerate successful hybrid customer engagement that support new and more agile go-to-market models.

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has invested in Tact.ai, the customer engagement company for life sciences. Tact.ai helps pharmaceutical companies work more effectively with health care professionals (HCPs) to deliver innovative medicines to patients faster. The investment is the fourth Life Sciences industry investment in the past six months for Tact.ai, following its $33 million USD fundraise...